lithium carbonate 450 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Lithium Carbonate Extended-Release Tablets are indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, Lithium Carbonate Extended-Release Tablets may produce a normalization of symptomatology within 1 to 3 weeks.

American Health Packaging

FDA Reported Adverse Reactions
`[1] pain` `[2] fatigue` `[3] drug ineffective` `[4] nausea` `[5] headache` `[6] off label use` `[7] dyspnoea` `[8] diarrhoea` `[9] vomiting` `[10] arthralgia`

1 year ago

ROUND WHITE 54 346

1 year ago

54 346 ROUND WHITE

HOW SUPPLIED

LITHIUM CARBONATE Extended-Release Tablets USP 450 mg tablets are speckled, off-white to yellow, round biconvex tablets with “54 346” debossed on one side and scored on the other side. Unit dose packages of 100 (10 x 10) NDC 68084-655-01 Storage Conditions Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] FOR YOUR PROTECTION: Do not use if blister is torn or broken.

More pills like ROUND 54 346

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

lithium carbonate 450 MG Extended Release Oral Tablet

FDA Reported Adverse Reactions [1] pain [2] fatigue [3] drug ineffective [4] nausea [5] headache [6] off label use [7] dyspnoea [8] diarrhoea [9] vomiting [10] arthralgia

ROUND WHITE 54 346

54 346 ROUND WHITE

More pills like ROUND 54 346

FDA Reported Adverse Reactions
`[1] pain` `[2] fatigue` `[3] drug ineffective` `[4] nausea` `[5] headache` `[6] off label use` `[7] dyspnoea` `[8] diarrhoea` `[9] vomiting` `[10] arthralgia`